<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-162651" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anticoagulant Therapy In Pregnancy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zaidi</surname>
            <given-names>Syed Rafay H.</given-names>
          </name>
          <aff>Parkview Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jenkins</surname>
            <given-names>Suzanne M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Syed Rafay Zaidi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Suzanne Jenkins declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-162651.s1" sec-type="Summary / Explanation">
        <title>Summary / Explanation</title>
        <p content-type="pubmed-excerpt">Pregnancy is a complex physiologic state that presents unique challenges, particularly when managing medical conditions that require anticoagulant therapy. Anticoagulant therapy plays a crucial role in preventing and managing thromboembolic events, which can be particularly challenging during pregnancy due to the hypercoagulable state that naturally occurs. Pregnant women are at an increased risk of venous thromboembolism (VTE) due to hormonal changes, increased blood volume, and changes in blood flow. The preferred anticoagulants for treating and preventing VTE in most pregnant patients include low molecular weight heparins (LMWH) and unfractionated heparin (UFH). Vitamin K antagonists (eg, warfarin), on the other hand, are known teratogens and, therefore, relatively contraindicated except in patients at extremely high risk for VTE (eg, those with mechanical heart valves). For these extremely high-risk patients, there is no clearly preferred anticoagulant, and the agent chosen must be individualized through a shared decision-making process between the patient and the healthcare team.<xref ref-type="bibr" rid="article-162651.r1">[1]</xref></p>
        <p>The delicate balance between preventing thromboembolic events in the mother and ensuring the safety of the developing fetus makes anticoagulant therapy in pregnancy a topic of great importance. This article explores the various aspects of anticoagulant therapy during pregnancy, focusing on special considerations that healthcare professionals must consider.<xref ref-type="bibr" rid="article-162651.r2">[2]</xref></p>
        <p>
<bold>Anticoagulant Recommendations During Pregnancy</bold>
</p>
        <p>Selecting the appropriate anticoagulant during pregnancy involves careful consideration of both maternal and fetal factors. The choice must strike a balance between effectively preventing thromboembolic events in the mother and minimizing potential risks to the developing fetus. Several factors influence the decision-making process, and clinicians must tailor their choices based on each pregnant individual's unique characteristics and medical history.<xref ref-type="bibr" rid="article-162651.r3">[3]</xref><xref ref-type="bibr" rid="article-162651.r4">[4]</xref>&#x000a0;The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine have both published guidelines to help inform this choice.<xref ref-type="bibr" rid="article-162651.r4">[4]</xref><xref ref-type="bibr" rid="article-162651.r1">[1]</xref></p>
        <p>
<bold>Low-Molecular-Weight Heparin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Advantages</bold>
<list list-type="bullet"><list-item><p>LMWH (eg, enoxaparin or dalteparin) is typically the preferred choice for treatment and prophylaxis of VTE during pregnancy due to their efficacy, predictable pharmacokinetics, and safety profiles.</p></list-item><list-item><p>These agents do not cross the placenta in significant quantities, reducing the risk of adverse effects on fetal development.</p></list-item><list-item><p>LMWHs are available in pre-filled syringes, offering convenient subcutaneous administration without the need for frequent laboratory monitoring.<xref ref-type="bibr" rid="article-162651.r5">[5]</xref><xref ref-type="bibr" rid="article-162651.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Considerations</bold>
<list list-type="bullet"><list-item><p>Therapeutic dosing (ie, for treatment of a current VTE) is weight-based during pregnancy.</p></list-item><list-item><p>Dosing adjustments should be made as recommended throughout gestation, especially in cases of obesity or extreme body weight.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Unfractionated Heparin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Advantages</bold>
<list list-type="bullet"><list-item><p>UFH is a suitable alternative when LMWH is contraindicated or when more immediate reversibility is required.<xref ref-type="bibr" rid="article-162651.r7">[7]</xref></p></list-item><list-item><p>Unlike LMWH, UFH has a shorter half-life, facilitating quicker discontinuation in the event of urgent interventions or impending labor.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Considerations</bold>
<list list-type="bullet"><list-item><p>UFH requires frequent monitoring of activated partial thromboplastin time (aPTT) to maintain therapeutic drug levels.</p></list-item><list-item><p>Dosing adjustments may be necessary as indicated by aPTT target.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Relative Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Warfarin</bold>
<list list-type="bullet"><list-item><p>Warfarin crosses the placenta and has been associated with an increased risk of embryopathy, particularly when used during the first trimester.<xref ref-type="bibr" rid="article-162651.r8">[8]</xref></p></list-item><list-item><p>Due to its potential teratogenic effects, warfarin is generally avoided in pregnancy, especially during organogenesis.</p></list-item><list-item><p>Warfarin is generally contraindicated during pregnancy, except in cases where the benefits outweigh the risks, such as in patients with mechanical heart valves.<xref ref-type="bibr" rid="article-162651.r9">[9]</xref><xref ref-type="bibr" rid="article-162651.r10">[10]</xref>&#x000a0;</p></list-item><list-item><p>In patients with mechanical heart valves, warfarin is the preferred agent in nonpregnant individuals because its use leads to the lowest risk of valve thrombosis. Clinicians and patients must weigh the risk of valve thrombosis against the risk of congenital anomalies and make an individualized anticoagulation plan. Some patients may choose an LMWH in the first trimester, switching back to warfarin for the remainder of pregnancy.<xref ref-type="bibr" rid="article-162651.r1">[1]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Direct oral anticoagulants&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Limited data are available on direct oral anticoagulants (DOACs)<bold>&#x000a0;</bold>safety during pregnancy, and therefore generally not recommended.<xref ref-type="bibr" rid="article-162651.r11">[11]</xref></p></list-item><list-item><p>Placental transfer and potential effects on fetal development vary among different DOACs.</p></list-item><list-item><p>DOACs also should not be used during breastfeeding due to&#x000a0;increased reproductive risks in animal studies and insufficient human safety and efficacy data.<xref ref-type="bibr" rid="article-162651.r12">[12]</xref><xref ref-type="bibr" rid="article-162651.r13">[13]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Peripartum Anticoagulant Therapy</bold>
</p>
        <p>Anticoagulation can increase the risk of epidural or spinal hematoma with neuraxial anesthesia. Therefore, patients receiving prophylactic LMWH during pregnancy are advised to discontinue anticoagulation at least 12 hours before a scheduled induction of labor or cesarean delivery. For pregnant women on adjusted-dose LMWH therapy with a planned delivery, LMWH discontinuation at least 24 hours before the scheduled induction of labor, cesarean section, or the anticipated time of neuraxial anesthesia is recommended, instead of maintaining LMWH up until the moment of delivery. In anticipation of delivery, women on anticoagulation therapy may be switched from&#x000a0;a LMWH to UFH, which has a shorter half-life based on the institution's protocol.&#x000a0;For patients on prophylactic LMWH during pregnancy, clinicians should wait at least 12 hours after neuraxial blockade and at least 4 hours after catheter removal to restart LMWH prophylaxis. For patients on intermediate or adjusted-dose LMWH, consider waiting at least 24 hours after neuraxial blockade and at least 4 hours after catheter removal to restart LMWH anticoagulation.<xref ref-type="bibr" rid="article-162651.r14">[14]</xref></p>
        <p>
<bold>Special Considerations for Anticoagulation Therapy in Pregnancy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dosing adjustments</bold>:&#x000a0;Pregnancy induces physiologic changes, including an increase in blood volume and changes in renal function. These alterations can impact the pharmacokinetics of anticoagulant drugs. Therefore, careful dosing adjustments are crucial to maintain therapeutic levels while minimizing the risk of bleeding.<xref ref-type="bibr" rid="article-162651.r15">[15]</xref>&#x000a0;Adjusted-dose (ie, therapeutic) LMWH regimens are weight-based, so dosing may require adjustments as a patient's weight naturally increases throughout pregnancy.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Monitoring and laboratory tests</bold>: Regular monitoring with laboratory testing is sometimes needed to ensure efficacy and safety. Patients on UFH should be monitored to maintain an aPTT in the therapeutic range of 1.5 to 2.5 times the control 6 hours after the injection. Anticoagulation with LMWH can be monitored by following anti-factor Xa levels. However, the need to monitor these patients remains uncertain. For those on weight-based therapeutic doses, studies in which anti-factor Xa levels have been monitored with a goal of 0.6 to 1.0 units/mL, show that few patients will require dosing adjustments beyond those they would already receive as their weight naturally increases during pregnancy. The decision to monitor patients on therapeutic LMWH should, therefore, be based on institutional protocols and clinical judgment. Additionally, optimal anti-factor Xa levels have not been determined for patients receiving prophylactic LMWH, so patients on prophylactic doses rarely require regular monitoring. Finally, close attention should be given to routine laboratory tests, including platelet counts, to detect any signs of adverse effects of the anticoagulants (eg, heparin-induced thrombocytopenia).<xref ref-type="bibr" rid="article-162651.r16">[16]</xref><xref ref-type="bibr" rid="article-162651.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fetal risk</bold>:&#x000a0;While LMWH and UFH are considered safer options than vitamin K antagonists, a potential risk of adverse fetal outcomes (eg, bleeding at the uteroplacental junction) still exists. Clinicians must weigh the benefits of anticoagulation for the mother against potential risks to the fetus. Communication with the patient about these considerations is crucial for informed decision-making.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Timing of anticoagulant initiation and discontinuation</bold>:&#x000a0;Initiating anticoagulant therapy early in pregnancy may be necessary for women with a history of thromboembolism or certain high-risk conditions (eg, thrombophilia and some cardiovascular disease). However, the timing of initiation and discontinuation must be carefully planned to minimize bleeding risks during labor and delivery.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neonatal monitoring</bold>:&#x000a0;Neonates born to mothers receiving anticoagulant therapy may be at an increased risk of bleeding complications. Pediatric clinicians should be informed that close monitoring for bleeding tendencies is essential during the neonatal period.<xref ref-type="bibr" rid="article-162651.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patient education and compliance</bold>:&#x000a0;Patient education is paramount. Women on anticoagulant therapy during pregnancy must be well-informed about the importance of medication compliance, signs of bleeding or thrombosis, and the necessity of close follow-up with clinicians.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Individualized decision-making</bold>:&#x000a0;The choice of anticoagulant should be individualized based on the woman's medical history, anticoagulation indication, and overall health. Consultation with a multidisciplinary team, including obstetricians, hematologists, and maternal-fetal medicine specialists, is crucial in making informed decisions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patient preferences and adherence</bold>:&#x000a0;Involving the pregnant individual in decision-making is essential. Understanding patient preferences, lifestyle, and the ability to comply with the prescribed regimen enhances medication adherence.</p>
          </list-item>
        </list>
        <p>
<bold>Conclusion</bold>
</p>
        <p>Anticoagulant therapy in pregnancy requires a delicate balance between preventing thromboembolic events in the mother and ensuring the safety of the developing fetus. Special considerations, including dosing adjustments, monitoring, and careful evaluation of fetal risks, are essential components of managing anticoagulant therapy during pregnancy. Through a collaborative effort between clinicians and pregnant individuals, optimal outcomes can be achieved, safeguarding the well-being of both the mother and the unborn child. The benefits of preventing thromboembolic events must be carefully weighed against potential risks to the fetus. Clinicians should engage in open communication with pregnant individuals, empowering them to participate in decisions about their anticoagulant therapy actively, and fostering a collaborative approach to maternal and fetal health. In conclusion, the selection of anticoagulant therapy during pregnancy requires a thoughtful and individualized approach.<xref ref-type="bibr" rid="article-162651.r19">[19]</xref></p>
      </sec>
      <sec id="article-162651.s2">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=162651&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=162651">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/162651/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=162651">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-162651.s3">
        <title>References</title>
        <ref id="article-162651.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org</collab>
              <name>
                <surname>Pacheco</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Saade</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shrivastava</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shree</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elkayam</surname>
                <given-names>U</given-names>
              </name>
              <collab>Publications Committee</collab>
            </person-group>
            <article-title>Society for Maternal-Fetal Medicine Consult Series #61: Anticoagulation in pregnant patients with cardiac disease.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>227</volume>
            <issue>2</issue>
            <fpage>B28</fpage>
            <page-range>B28-B43</page-range>
            <pub-id pub-id-type="pmid">35337804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Safarzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation Regimens in Pregnancy.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>241</fpage>
            <page-range>241-249</page-range>
            <pub-id pub-id-type="pmid">36822707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation in pregnancy complications.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2014</year>
            <month>Dec</month>
            <day>05</day>
            <volume>2014</volume>
            <issue>1</issue>
            <fpage>393</fpage>
            <page-range>393-9</page-range>
            <pub-id pub-id-type="pmid">25696884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>132</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e17</page-range>
            <pub-id pub-id-type="pmid">29939938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grandone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The prevention and treatment of venous thromboembolism in pregnancy.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2017</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>397</fpage>
            <page-range>397-402</page-range>
            <pub-id pub-id-type="pmid">28425765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Carolis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>di Pasquo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Del Sordo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buonomo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schiavino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lanzone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Fondaparinux in pregnancy: Could it be a safe option? A review of the literature.</article-title>
            <source>Thromb Res</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>135</volume>
            <issue>6</issue>
            <fpage>1049</fpage>
            <page-range>1049-51</page-range>
            <pub-id pub-id-type="pmid">25912931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>[Risk factors and therapeutic strategies of deep venous thrombosis during pregnancy].</article-title>
            <source>Zhonghua Yi Xue Za Zhi</source>
            <year>2010</year>
            <month>Nov</month>
            <day>30</day>
            <volume>90</volume>
            <issue>44</issue>
            <fpage>3140</fpage>
            <page-range>3140-3</page-range>
            <pub-id pub-id-type="pmid">21211346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yurdak&#x000f6;k</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fetal and neonatal effects of anticoagulants used in pregnancy: a review.</article-title>
            <source>Turk J Pediatr</source>
            <year>2012</year>
            <season>May-Jun</season>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-15</page-range>
            <pub-id pub-id-type="pmid">23094528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leyh</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruhparwar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haverich</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulant therapy in pregnant women with mechanical heart valves.</article-title>
            <source>Arch Gynecol Obstet</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>268</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">12673466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassouna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allam</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis.</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>797</fpage>
            <page-range>797-806</page-range>
            <pub-id pub-id-type="pmid">24595247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Areia</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Mota-Pinto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Experience with direct oral anticoagulants in pregnancy&#x000a0;- a systematic review.</article-title>
            <source>J Perinat Med</source>
            <year>2022</year>
            <month>May</month>
            <day>25</day>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-461</page-range>
            <pub-id pub-id-type="pmid">35073471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bates</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Veenstra</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Prabulos</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vandvik</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e691S</fpage>
            <page-range>e691S-e736S</page-range>
            <pub-id pub-id-type="pmid">22315276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arachchillage</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beyer-Westendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abdul-Kadir</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH.</article-title>
            <source>J Thromb Haemost</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>1673</fpage>
            <page-range>1673-6</page-range>
            <pub-id pub-id-type="pmid">27346676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skeith</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>2021</volume>
            <issue>1</issue>
            <fpage>559</fpage>
            <page-range>559-569</page-range>
            <pub-id pub-id-type="pmid">34889418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bistervels</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Buchm&#x000fc;ller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiegers</surname>
                <given-names>HMG</given-names>
              </name>
              <name>
                <surname>N&#x000ed; &#x000c1;inle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tardy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Rodger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeSancho</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Shmakov</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>van Es</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chauleur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <collab>Highlow Block writing committee</collab>
              <collab>Highlow Investigators</collab>
            </person-group>
            <article-title>Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Nov</month>
            <day>19</day>
            <volume>400</volume>
            <issue>10365</issue>
            <fpage>1777</fpage>
            <page-range>1777-1787</page-range>
            <pub-id pub-id-type="pmid">36354038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Efthymiou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devreese</surname>
                <given-names>KMJ</given-names>
              </name>
            </person-group>
            <article-title>Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.</article-title>
            <source>J Thromb Haemost</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>892</fpage>
            <page-range>892-908</page-range>
            <pub-id pub-id-type="pmid">33325604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasich</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Keren-Politansky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jabareen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalish</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schliamser</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nadir</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Effects of anti-Xa activity monitoring on the outcome of high-risk pregnancies treated with a prophylactic dose of low-molecular-weight heparin.</article-title>
            <source>Eur J Haematol</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>111</volume>
            <issue>4</issue>
            <fpage>655</fpage>
            <page-range>655-661</page-range>
            <pub-id pub-id-type="pmid">37533300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rambiritch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Paek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sayre</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leisegang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-40</page-range>
            <pub-id pub-id-type="pmid">31673991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162651.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shatzel</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Salati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DeLoughery</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>The Safety of Low-Molecular-Weight Heparin During and After Pregnancy.</article-title>
            <source>Obstet Gynecol Surv</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>721</fpage>
            <page-range>721-729</page-range>
            <pub-id pub-id-type="pmid">29280473</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
